These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 25539608)

  • 1. [Fourth-line and beyond therapy in advanced non-small cell lung cancer: a retrospective analysis].
    Wang X; Huang M; Ren L; Xu Y; Li L; Hou M; Wang J; Peng F; Zhu J; Wang Y; Lu Y
    Zhongguo Fei Ai Za Zhi; 2014 Dec; 17(12):839-44. PubMed ID: 25539608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
    Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Lee SY
    Lung Cancer; 2015 Feb; 87(2):155-61. PubMed ID: 25488862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of first-line chemotherapy affects the second-line setting response in patients with advanced non-small cell lung cancer.
    Cao W; Li AW; Ren SX; Chen XX; Li W; Gao GH; He YY; Zhou CC
    Asian Pac J Cancer Prev; 2014; 15(16):6799-804. PubMed ID: 25169528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
    Lee JY; Lim SH; Kim M; Kim S; Jung HA; Chang WJ; Choi MK; Hong JY; Lee SJ; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2014 May; 73(5):1063-70. PubMed ID: 24663503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third-line therapy in advanced non-small cell lung cancer.
    Ying Geng Z; Chang Jiao S; Cui Liu S; Li Y; Feng Liu Z; Qing Zhang G; Jie Wang L; Qu F
    J BUON; 2013; 18(4):899-907. PubMed ID: 24344015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.
    Berardi R; Rinaldi S; Santoni M; Newsom-Davis T; Tiberi M; Morgese F; Caramanti M; Savini A; Ferrini C; Torniai M; Fiordoliva I; Bower M; Cascinu S
    Oncotarget; 2016 May; 7(18):26916-24. PubMed ID: 27029035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.
    Suzuki H; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Kawase I
    Asia Pac J Clin Oncol; 2015 Jun; 11(2):121-8. PubMed ID: 24811212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.
    Hayashi H; Okamoto I; Taguri M; Morita S; Nakagawa K
    Clin Lung Cancer; 2013 May; 14(3):261-6. PubMed ID: 23107465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment].
    Wang X; Zhang W; Du W; Zhang X; Ren X; Cao S
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):761-768. PubMed ID: 29167006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer.
    Wang Z; Zhu XX; Wu XH; Li B; Shen TZ; Kong QT; Li J; Liu ZB; Jiang WR; Wang Y; Hou B
    Am J Clin Oncol; 2014 Apr; 37(2):148-53. PubMed ID: 23211223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China.
    Liu YR; Zhu W; Zhang JL; Huang JQ; Zhao YZ; Zhang W; Han BH; Yao YH; Jiang LY; Li SQ
    Clin Respir J; 2014 Apr; 8(2):206-12. PubMed ID: 24118906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
    Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R
    J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
    Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T
    Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
    Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL
    Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.
    Buti S; Bordi P; Tiseo M; Bria E; Sperduti I; Di Maio M; Panni S; Novello S; Rapetti SG; Pilotto S; Genestreti G; Rossi A; Pezzuolo D; Camisa R; Tortora G; Ardizzoni A
    Lung Cancer; 2015 Jun; 88(3):319-24. PubMed ID: 25870156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
    Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
    Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
    Kumarakulasinghe NB; Syn N; Soon YY; Asmat A; Zheng H; Loy EY; Pang B; Soo RA
    Oncotarget; 2016 Dec; 7(51):85542-85550. PubMed ID: 27907909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.